Blue Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$801K Sell
1,533
-144
-9% -$73.7K 0.01% 346
2026
Q2
$833K Buy
1,677
+1,252
+295% +$555K 0.01% 339
2026
Q1
$190K Sell
425
-912
-68% -$425K ﹤0.01% 790
2025
Q4
$606K Buy
1,337
+769
+135% +$331K 0.01% 421
2025
Q3
$222K Sell
568
-24
-4% -$10K ﹤0.01% 758
2025
Q2
$264K Buy
592
+19
+3% +$8.76K ﹤0.01% 669
2025
Q1
$278K Sell
573
-61
-10% -$28.4K ﹤0.01% 590
2024
Q4
$255K Sell
634
-2,077
-77% -$963K ﹤0.01% 567
2024
Q3
$1.27M Buy
2,711
+1,268
+88% +$609K 0.02% 220
2024
Q2
$603K Buy
1,443
+1,248
+640% +$542K 0.01% 323
2024
Q1
$81.5K Sell
195
-303
-61% -$128K ﹤0.01% 768
2023
Q4
$173K Sell
498
-628
-56% -$232K ﹤0.01% 493
2023
Q3
$397K Buy
1,126
+108
+11% +$37.8K 0.01% 291
2023
Q2
$321K Sell
1,018
-189
-16% -$63.7K 0.01% 296
2023
Q1
$349K Sell
1,207
-42
-3% -$12.6K 0.01% 369
2022
Q4
$361K Buy
1,249
+1,006
+414% +$307K 0.01% 317
2022
Q3
$68K Buy
243
+113
+87% +$32.5K ﹤0.01% 652
2022
Q2
$34K Buy
+130
New +$34.8K ﹤0.01% 806

Other funds holding VRTX

Blue Trust's VRTX Position: Q3 2026 in Review

Blue Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 8.6% in Q3 2026, selling an estimated $73.7K and leaving 1,533 shares worth $801K. The position accounts for 0.01% of the portfolio, ranked #346.

Blue Trust first reported a position in VRTX in Q2 2022 and has held it in 18 quarters since. The position peaked at $1.27M in Q3 2024. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Blue Trust held 1,533 shares of Vertex Pharmaceuticals worth $801K as of Q3 2026.
  • Blue Trust sold 144 Vertex Pharmaceuticals shares in Q3 2026, an estimated $73.7K.
  • Vertex Pharmaceuticals made up 0.01% of Blue Trust's portfolio in Q3 2026, its #346 holding.
  • Blue Trust first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 18 quarters since.
  • Blue Trust's Vertex Pharmaceuticals position peaked at $1.27M in Q3 2024.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.